Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

صناعة

Biotechnology

قطاع

Healthcare

المقر الرئيسي

US

المدير التنفيذي

Tien-Li Lee

المدرجة منذ ذلك الحين

13 فبراير 2025

موظفين

28